Research programme: integrated stress response modulators - HiberCell
Latest Information Update: 18 Feb 2021
At a glance
- Originator HiberCell
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 02 Feb 2021 Research programme: integrated stress response modulators - HiberCell is available for licensing as of 02 Feb 2021. https://www.hibercell.com/find-us/
- 02 Feb 2021 Preclinical trials in Haematological malignancies in USA (PO) before February 2021 (HiberCell pipeline, February 2021)
- 02 Feb 2021 Preclinical trials in Solid tumours in USA (PO) before February 2021 (HiberCell pipeline, February 2021)